Navigation Links
The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
Date:5/18/2009

ly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

Important Additional Information

The Quigley Corporation ("Quigley" or the "Company") filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") on April 2, 2009 in connection with the 2009 Annual Meeting of Stockholders and began the process of mailing the definitive proxy statement and a WHITE proxy card to stockholders. The Company's stockholders are strongly advised to read Quigley's proxy statement as it contains important information. Stockholders may obtain an additional copy of Quigley's definitive proxy statement and any other documents filed by the Company with the SEC for free at the SEC's website at http://www.sec.gov. Copies of the
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
2. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
3. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
4. The Quigley Corporation Reports First Quarter 2009 Results
5. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
6. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
7. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
8. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
9. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
10. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
11. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... NY (PRWEB) , ... August 04, 2015 , ... ... vegetarian capsule formula. Healthy Origins® Cognizin® is a trademark for Citicoline, a ... base for a capsule for those applications which have more of a semi-solid ...
(Date:8/4/2015)... ... August 04, 2015 , ... An article published July 27th by ... viable method for encouraging people to lose weight. Specifically the study compared control patients ... loss success, adding a financial incentive to the overall incentive of increased health. According ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... commercial customers. Finding reliable hardware can be difficult and troublesome for companies. ... an office together or designing a new facility, it is imperative to include ...
(Date:8/4/2015)... ... August 04, 2015 , ... Bayco Products, Inc. announces a new industrial-grade LED ... on hard hats that have a flip-up face shield. The sleek contours of the ... without having to remove their headlamp when raising or lowering their face shield or ...
(Date:8/4/2015)... ... , ... Angelina Jolie is in it at age 39. “It” is menopause, ... Angela DeRosa, DO, MBA, CPE aka “Dr. Hot Flash,” arguably the Southwest’s leading ... menopause. , Myth #1: Menopause only affects old ladies. – Menopause can affect ...
Breaking Medicine News(10 mins):Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 3Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 4Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3
... Bad Reactions to FDA Safety,Program, WASHINGTON, April 2, 2008 ... Americans who have ever taken a,prescription drug experienced a side ... but the majority of consumers don,t know they can,report these ... safety problems., To help make the public aware of ...
... 2, 2008) Dr. Richard Stein, a professor emeritus ... Dentistry, has been named the 2007 recipient of the ... prize is presented annually to the top ranked spinal ... Research,s (CIHR) investigator-initiated grants competition. , Stein ...
... WEDNESDAY, April 2 (HealthDay News) -- Two well-known HIV ... of heart attacks, European researchers reported Wednesday. , Based ... is now conducting a safety review of the potential ... take a combination of antiretroviral drugs, which include a ...
... GXDX ) today announced that the company,s 2008 annual meeting,of ... June 17, 2008 at,the company,s headquarters in Carlsbad, CA., ... business on,April 25, 2008 as the record date for the ... to vote at, the annual meeting., About Genoptix, Inc., ...
... ORLANDO, Fla., April 2, 2008 The American,Red ... assistance and,other benefits to Hurricane Katrina and Rita ... Louisiana and south Mississippi. These,funds, initially set aside ... are being used to bolster existing individual,assistance through ...
... YORK, April 2, 2008 Easter Seals is shining ... among the,vast array of services the national nonprofit provides ... the last 20 years, Easter Seals has seen a ... autism the organization serves.,Today, as many as one in ...
Cached Medicine News:Health News:Consumer Reports Poll: Most Say TV Drug Ads Should Include Info on How to Report Side Effects 2Health News:Consumer Reports Poll: Most Say TV Drug Ads Should Include Info on How to Report Side Effects 3Health News:Alberta physiologist earns top national honor for spinal cord research 2Health News:HIV Drugs Linked to Increased Risk of Heart Attack 2Health News:HIV Drugs Linked to Increased Risk of Heart Attack 3Health News:In Face of Continuing Katrina and Rita Needs Red Cross Adds Resources to Gulf Coast 2Health News:In Face of Continuing Katrina and Rita Needs Red Cross Adds Resources to Gulf Coast 3Health News:Easter Seals Celebrates World Autism Awareness Day With Campaign to Highlight Nationwide Services Available to Families Living With Autism Today 2
(Date:8/4/2015)... 2015 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... and Chief Executive Officer, Doug Godshall , is ... Growth Conference at 8:30 a.m. EDT on Thursday, August ... 2015 at the InterContinental Boston. A live ...
(Date:8/4/2015)... Research and Markets ... the "MRI Systems Market to 2020 - ... Growth Driven by Developing Economies" report to ... 2020 - Focus on Patient Comfort and Operational ... the market, competitive landscape, and trends for three ...
(Date:8/4/2015)... 2015  Dr. Keesha Ewers of ... approval of flibanserin, or what is being touted ... of decreased female sexual desire back several decades. ... and addressing libido as a singular symptom with ... Photo - ...
Breaking Medicine Technology:HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast 2Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5
... Vical Incorporated,(Nasdaq: VICL ) today announced ... independently produced video report featuring metastatic,melanoma patients treated ... is expected to be used,broadly by stations in ... Allovectin-7(R) trial, and in other cities by stations ...
... III Results Demonstrate Superior Reduction in In-Segment Late Loss, Non-Inferiority in ... ... V Compared to TAXUS, ABBOTT PARK, Ill., April ... Association (JAMA) demonstrated,that use of Abbott,s XIENCE(TM) V Everolimus Eluting Coronary ...
Cached Medicine Technology:Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report 2Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report 3Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report 4Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report 5Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 2Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 3Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 4Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 5
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
Sinus Trocar and Cannula, 4 mm...
1.0 mm diameter head, 0.75 mm deep bite....
Kelly Punches...
Medicine Products: